
For investors only
All about the drug candidate arfolitixorin
and related information
ASCO GI 2025, poster
An abstract with results from a post hoc-analysis of the company’s Phase III-study AGENT will be presented at ASCO GI, which takes place in San Francisco, US, between January 23-25th, 2025.
An external expert group consisting of Göran Carlsson, MD, PhD, Sahlgrenska University Hospital; Åke Hjalmarson, MD, Prof in Cardiology at Sahlgrenska University Hospital, and Aldina Pivodic, PhD, APNC Sweden. It is based on the post-hoc per-protocol analysis of the global phase III-study AGENT conducted earlier this year and is funded by Isofol.
Information about the poster
Title: ”The importance of treatment handling and compliance on overall response rate in a phase III study of metastatic colorectal cancer: Post-hoc per protocol analyses of the AGENT trial”.
Presenter: Aldina Pivodic, PhD, APNC Sweden
Abstract Number: #205
Poster Number: #Bd H17
The abstract was published online on January 21 at 16:00 CET.
The poster is presented on site on January 25 at 07:00 PST. Link to the poster session schedule.
Last updated 01-27-2025